AbbVie's First Quarter: Trying to Replace Humira Sales

Since AbbVie Inc.'s (NYSE: ABBV) inception, investors have been fretting about the eventual demise of its lead drug, Humira. The aging blockbuster has slowed down a bit during the first three months of the year, but the rest of the company's product lineup stepped up and delivered.